Ponesimod Polymorphs T3 and T4 for Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current solid state forms of Ponesimod lack optimal stability and bioavailability, which are crucial for effective treatment of autoimmune diseases such as multiple sclerosis, necessitating the development of new crystalline polymorphs with improved physical and chemical properties.
Innovation Solution
The disclosure provides two new solid state forms, Form T3 and Form T4 of Ponesimod, characterized by specific X-ray powder diffraction patterns and prepared through controlled crystallization processes, which enhance solubility, stability, and handling characteristics, and these forms are combined with pharmaceutically acceptable excipients to create effective pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing solid state forms of Ponesimod are used, then the compound can be formulated for pharmaceutical use, but the stability and bioavailability are suboptimal
Solution Approach 1:
The patent applies parameter changes by discovering and characterizing new polymorphic forms (Form T3 and Form T4) of Ponesimod with different crystal structures. These polymorphs exhibit improved stability and bioavailability compared to previously known forms, directly resolving the contradiction between achieving optimal pharmaceutical performance and ease of formulation.
Solution Approach 2:
The patent creates composite pharmaceutical compositions that incorporate specific polymorphic forms of Ponesimod with excipients. By selecting and combining particular polymorphic forms with compatible excipients, the patent achieves both improved stability and enhanced bioavailability while maintaining formulation feasibility.
2Reliability
If existing solid state forms of Ponesimod are used, then the compound can be processed, but the bioavailability is insufficient for effective treatment
Solution Approach 1:
The patent utilizes parameter changes by identifying polymorphic forms with superior dissolution and absorption characteristics. Form T3 and Form T4 demonstrate enhanced bioavailability parameters compared to previous forms, directly addressing the insufficient bioavailability issue and improving treatment effectiveness.
3Reliability
If new solid state forms are developed, then improved stability and solubility can be achieved, but the complexity of characterizing and processing these forms increases
Solution Approach 1:
The patent manages characterization complexity by systematically defining and characterizing the new polymorphic forms using standard analytical techniques. By establishing clear characterization parameters for Form T3 and Form T4, the patent balances the achievement of improved solubility with manageable characterization requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new solid state forms of Ponesimod, particularly Form T3 and Form T4, demonstrate improved solubility and stability, offering enhanced therapeutic efficacy and improved handling properties, making them suitable for the treatment of autoimmune diseases like multiple sclerosis.
Implementation Method 1
The disclosure provides two new solid state forms, Form T3 and Form T4 of Ponesimod, characterized by specific X-ray powder diffraction patterns and prepared through controlled crystallization processes
Data Source
AI summary
The present disclosure encompasses Ponesimod crystalline forms, processes for preparation thereof, and pharmaceutical compositions thereof.